AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...

Variant Bio recently announced a multimillion-dollar deal with a pharmaceutical company, and some of that money will go to ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

At the J.P. Morgan Healthcare Conference, the Biotech CEO Sisterhood assembled in Union Square to showcase the large group of ...

In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a ...

A Huntsville-based biotechnology company has secured $10 million in funding to begin the trial of a new way to deliver medication to advanced Parkinson’s disease patients.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...